摘要
目的基于超高效液相色谱联用四极杆-静电场轨道阱高分辨质谱仪(UPLC-Q-Exactive-MS)代谢组学技术,研究蒙药塔布森-2(由杜仲和蓝刺头配伍而成)对去势大鼠代谢的调控作用。方法 Wistar雌性大鼠随机分为空白组、假手术组、模型组、结合雌激素组(0.065 mg/kg)、骨疏康颗粒组(105.1 mg/kg)和蒙药塔布森-2高、中、低剂量(950、475、237.5 mg/kg)组,每组6只。大鼠进行卵巢摘除术后1周,进行阴道上皮细胞角质化实验,检测造模成功后,各给药组ig相应药物,空白组、假手术组和模型组ig等体积0.9%氯化钠溶液,1次/d,持续8周。末次给药24h后,采集各组大鼠的粪便尿液,进行UPLC-Q-Exactive-MS检测。结果尿液样本中,共鉴定出28个潜在生物标志物及8条代谢通路与蒙药塔布森-2治疗绝经后骨质疏松症有关;粪便样本中,共鉴定出28个潜在生物标志物及7条代谢通路与蒙药塔布森-2治疗绝经后骨质疏松症有关。结论蒙药塔布森-2主要通过调节组氨酸代谢、牛磺酸和亚牛磺酸代谢、丙氨酸及天冬氨酸和谷氨酸代谢、维生素B6代谢,治疗绝经后骨质疏松症。
Objective To explore the effect of Mongolian medicine Tubson-2(塔布森-2, combined with Eucommia ulmoides and Echinops grijsii) on metabolism in ovariectomized rats based on UPLC-Q-Exactive-MS metabonomics technology. Methods Female Wistar rats were randomly divided into blank group, sham group, model group, conjugated estrogen group(0.065 mg/kg), Gushukang Granule group(105.1 mg/kg), high-, medium-and low-dose Mongolian medicine Tubson-2(950, 475, 237.5 mg/kg) groups, with six animals in each group. One week after ovarian extraction, rats were subjected to vaginal epithelial cell keratinization experiments. After successful modeling, rats in each administration group were ig corresponding drugs, rats in blank group, sham group and model group were ig 0.9% sodium chloride solution, once a day for 8 weeks. 24 h after the last administration, feces and urine of rats in each group were collected for UPLC-Q-Exactive-MS detection. Results A total of 28 potential biomarkers and eight metabolic pathways were identified in urine samples related to the treatment of postmenopausal osteoporosis by Mongolian medicine Tubson-2;A total of 28 potential biomarkers and seven metabolic pathways were identified in feces samples related to the treatment of postmenopausal osteoporosis by Mongolian medicine Tubson-2. Conclusion Mongolian medicine Tubson-2 mainly regulates histidine metabolism, taurine and hypotaurine metabolism, alanine, aspartic acid and glutamate metabolism and vitamin B6 metabolism to treat postmenopausal osteoporosis.
作者
杨帆
冯文斌
董馨
马飞祥
陆景坤
薛培凤
YANG Fan;FENG Wen-bin;DONG Xin;MA Fei-xiang;LU Jing-kun;XUE Pei-feng(Department of Pharmacy,Inner Mongolia Medical University,Hohhot 010110,China;Department of Pharmacy,China Mongolia Hospital of Hulun Buir,Hulun Buir 021000,China)
出处
《中草药》
CAS
CSCD
北大核心
2021年第19期5939-5947,共9页
Chinese Traditional and Herbal Drugs
基金
国家自然科学基金资助项目(81860756)
国家自然科学基金资助项目(81960758)
内蒙古自治区科技创新引导奖励资金项目(02039001)
内蒙古医科大学整合药理学蒙药药效物质基础研究团队专项(NYTD-2018001)。